Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment

ANNA SZUMERA-CIEĆKIEWICZ, JAN POLESZCZUK, EWA PASZKIEWICZ-KOZIK, GRZEGORZ RYMKIEWICZ, KAMIL SOKÓŁ, ANITA BORYSIUK, MARTYNA KOTARSKA, DARIA OWCZAREK, MONIKA KAWECKA, BEATA PYTLAK, JAN WALEWSKI and MONIKA PROCHOREC-SOBIESZEK
Anticancer Research December 2020, 40 (12) 6685-6697; DOI: https://doi.org/10.21873/anticanres.14692
ANNA SZUMERA-CIEĆKIEWICZ
1Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: szumann@gmail.com
JAN POLESZCZUK
3Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
4Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EWA PASZKIEWICZ-KOZIK
5Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GRZEGORZ RYMKIEWICZ
1Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
6Flow Cytometry Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAMIL SOKÓŁ
1Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANITA BORYSIUK
6Flow Cytometry Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARTYNA KOTARSKA
5Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DARIA OWCZAREK
1Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MONIKA KAWECKA
1Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BEATA PYTLAK
1Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAN WALEWSKI
5Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MONIKA PROCHOREC-SOBIESZEK
1Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Follicular lymphoma (FL) relapse within 24 months of the first immunochemotherapy (POD24) indicates more precisely poor overall survival and high risk of death. The aim of the study was to assess the potential value of POD24 in FL and describe the enhancer of zeste homolog 2 (EZH2) expression profile, in correlation with clinical/histopathological/immunophenotypical characteristics. Materials and Methods: This retrospective single-center study included 75 patients with FL treated under watch and wait (W&W) and immunochemotherapy regimens. All cases were immunohistochemically assessed: assays were performed for EZH2, CD10, BCL6, BCL2, MUM1, MYC and p53. Results: POD24 was independent of clinical/histopathological/immunohistochemical features and separated patients with inferior outcomes. EZH2 high expression was observed in high/low grade and follicular/diffuse FL patterns. BCL2-negative (p=0.042) and MUM1 (p=0.039), MYC (p<0.001), p53 (p<0.001) - positive cases had significantly higher EZH2 expression. Conclusion: POD24 is currently the most useful tool for the identification of poor outlook patients. EZH2 is crucial in FL biology, but the value of its protein expression is limited as a prognostic factor.

Key Words:
  • Follicular lymphoma
  • EZH2
  • POD24
  • time to first systemic therapy
  • prognostic factors
  • expression profile

Follicular lymphoma (FL) is an indolent B-cell lymphoma, but early relapse after first-line therapy occurs in up to 20% of patients (1-3). Different prognostic markers have been evaluated; however, the follicular International Prognostic Index (FLIPI) is still the only reproducible tool (4, 5). Its molecular modifications have not been yet widely accessible, while the next-generation sequencing-based genetic evaluation of FL is not a routine part of a diagnostic examination (6-8). Recently, the progression of disease within 24 months of first treatment (POD24) was applied for the identification of FL high-risk patients (3, 9). Early treatment failure is predictive of poor overall survival (10) and seems to be independent of initial treatment modality (11). Available results indicating the association of POD24 with prognostic markers, i.e., reduced intratumoral immune infiltration, pre-treatment positron-emission tomography-based staging, and molecular status, are still inconsistent and unsatisfactory (12, 13).

Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by the EZH2 gene. It is a functional component of polycomb repressive complex 2 (PRC2) and catalyzes the methylation of histone H3 lysine 27 (H3Kme27). EZH2 has a crucial role in transcription repression, development, and differentiation of healthy tissues. Conversely, in neoplastic cells, it activates transcription and stimulates proliferation. EZH2 alterations, both protein overexpression and mutations, were described in both solid tumors, i.e., breast (14-18), hepatocellular (19, 20), gastric (21), urothelial (22, 23), prostate carcinomas (24, 25), melanoma (26, 27) and in non-Hodgkin’s lymphomas (NHL) i.e., diffuse large B-cell lymphoma (DLBCL), FL, Burkitt lymphoma and other small cell and aggressive B-cell NHL (28, 29). The inferior impact of EZH2 overexpression on overall survival has been outlined independently (30).

EZH2 pathway includes the repression of cyclin-dependent kinase inhibitor CDKN1A, which is fundamental in the germinal center (GC) formation (31). In FL, which is GC-derived lymphoma, the EZH2 is constitutively activated and imprints repressive marks on both proliferation-checkpoint and terminal-differentiation genes (32, 33). One of the possible explanations of EZH2 protein loss is gain-of-function mutation related to tyrosine 646 EZH2 mutations have been reported in around 25% of FL (34, 35) and are believed to improve the clinical outcome. The EZH wild-type FL cases are associated with significantly increased risk of the early event. Therefore, the EZH2 gene status was included in the revised m7-FLIPI (7, 36). The recent results have shown that the prognostic value of the m7-FLIPI clinical and genetic model seems dependent on a therapeutic regimen (37). The results of EZH2 protein expression in FL are conflicting. Some studies have shown that a high level of EZH2 protein correlates with FL aggressiveness (29), but its microscopical visualization remains highly limited. Additionally, the latest observations have shown that EZH2 expression and distribution is far more complicated and related to many nongenetic causes (38, 39).

Moreover, the EZH2 pathways include close interactions with other essential genes, i.e., MYC, BCL-2, BCL-6, and TP53. Lately, the importance of cross-talk between MYC and TP53 (40, 41) as well as MYC and EZH2 (42, 43) is being discussed. The influence of MYC, BCL2, BCL6, or p53 protein expression in FL, on POD24, has not been yet thoroughly investigated.

Our study aims at EZH2 expression profiling in the FL, including its clinical impact. We focus on POD24 and time to first treatment within 24 months (TTFT24) analysis. The study illustrates the histopathological pattern of EZH2 expression concerning FL immunophenotype characteristics.

Materials and Methods

Study population. All FL cases were diagnosed at Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. The study protocol was approved by the Ethical Committee of Maria Sklodowska-Curie National Research Institute of Oncology. The study was conducted in accordance with the provisions of the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. All cases were reviewed and reclassified according to the revised 4th edition of the World Health Organization (WHO) diagnostic recommendations (6). The inclusion criteria were: pathologically proven diagnosis of FL grade 1, 2, or 3A, available formalin-fixed paraffin-embedded (FFPE) material, and clinical observation at least 5 years. Asymptomatic patients were observed according to the watch and wait (W&W) strategy until progression. Treatment was initiated in the presence of High Tumor Criteria in FL by Groupe d’Etude des Lymphomes Folliculaires (GELF). Patients received RCHOP or RCVP by individual physician decision (44, 45).

Immunohistochemistry. Tissue microarrays (TMA) were constructed; 3 cores of 1mm diameter from representative samples of lymphoma were incorporated. The positive (tonsil, testis, placenta) and negative (liver, kidney) controls were introduced in each TMA. Slides were stained with monoclonal anti-EZH2 antibody (clone: SP129, RTU, Ventana, Roche) reactive in paraffin-embedded tissue according to the manufacturer recommendation (Benchmark, Ventana, Roche, Tuscon, AZ, USA). The positive nuclear, strong (3+), and moderate (2+) EZH2 expression within the total area were evaluated via the semi-quantitative method by experienced hematopathologists (A.S.-C., K.S., M.P.-S.). The two categories, as previously described (46), included <70% (low EZH2) and ≥70% (high EZH2) of positive cells. The panel of antibodies for assessment of FL immunophenotype was used: CD10 (clone: 56C6, RTU, pH 9.0, Dako Omnis), BCL2 (clone: 124, RTU, pH 9.0, Dako Omnis), BCL6 (clone: PG-B6p, RTU, pH 9.0, Dako Omnis), MUM1 (clone: MUM1p, RTU, pH 9.0, Dako Omnis), MYC (clone: Y69, 1:100, pH 9.0, Abcam), and p53 (clone: DO-7, RTU, pH 9.0, Dako Omnis) were investigated onto FL cells. The evaluation cut-offs were defined as below: MUM1 – nuclear staining, high (>30%) or low (10-30%) expression, negative (<10% positive nuclei); MYC - nuclear staining, high (>40%) or low (10-40%) expression, negative (<10% positive nuclei); p53 - nuclear staining, high (>30%) or low (10-30%) expression, negative (<10% positive nuclei). All photographs were taken using the microscope camera DP72 Olympus BX53 (Olympus, Japan) with a spectrum of 2× – 400× magnification.

Statistical analysis. All statistical analyses were performed using R version 3.6.3 software (R Foundation for Statistical Computing, Vienna, Austria). Overall survival (OS) was defined as the time from diagnosis to the date of death or last contact date if the patient was still alive (censored observation). On treatment, progression-free survival (PFS) was defined as the time from treatment onset to progression or last contact date if progression did not occur (censored observation). Before treatment PFS for patients on W&W strategy was defined as the time from diagnosis to progression or last contact date if progression did not occur. POD24 was defined as one if the time from first therapy to the first documented progression was not greater than 24 months (high-risk POD24 group) and 0 otherwise (low-risk POD24 group). Introduction of first treatment within 24 months since diagnosis (TTF24) was defined analogously to POD24, but only for patients on W&W strategy. The Wilcoxon rank-sum and Pearson’s chi-square tests were used respectively to compare continuous and categorical factors between stratified cohorts. Multivariate Cox proportional hazard models were used to estimate hazard ratios (HRs).

Results

POD24 high-risk FL patients have a significantly worse overall survival. We included 75 patients diagnosed with FL with available tissue material. W&W and immunochemotherapy groups included respectively 31 and 44 patients. Patients who progressed on treatment within the first 24 months (POD24 – yes) had significantly worse overall survival compared to those that did not have progression within the first two years (Figure 1). HRs for patients with POD24, including clinical staging: age, gender, LDH and Hemoglobin levels, Ann Arbor Stage, treatment options, FLIPI1, and FLIPI2, were not significant. HRs for FL on treatment progression are shown in Figure 2.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Overall survival curve for patients who did or did not have progression of treatment within the first 24 months (POD24=yes and POD24=no, respectively). The dashed line indicates a 95% confidence interval.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Treatment progression hazard ratios (HRs) for the immunochemotherapy cohort from a multivariate Cox proportional hazards model.

EZH2 expression in FL is variable and non-homogenous. EZH2 expression was identified as high and low in 33.3% (25/75) and 66.7% (50/75) of FL cases, respectively. The expression was moderate to strong which was comparable to positive controls (Figure 3, compare upper photos with A, B, and C). Strong staining was identified within cells with centroblast-like morphology (Figure 3, arrows). The EZH2 expression loss was seen in cases of each histopathological grade (1 – 46.0%, 23/50; 2 – 40.0%, 20/50; and 3a – 14.0%, 7/50) including low and high-grade distribution (86.0%, 43/50 and 14.0%, 7/50, respectively) (Figure 3). The FL histopathological patterns (follicular, follicular/diffuse and diffuse) were similar in EZH high and low groups.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

EZH2 expression in follicular lymphoma (FL). The high and low-grade FL presented high and low EZH2 expression; the EZH2 was strongly expressed within centroblasts (arrows) (2× – 400×); the positive controls included (A) – testis (100×), (B) – reactive germinal centers of the tonsil (100×), (C) – placenta (100×).

The only clinical correlation between the EZH2 expression profile was age; older patients had higher EZH levels (60.5 vs. 52.0 years). Comparing EZH high to low groups and FL immunophenotype shows weak statistical differences in BCL2 and MUM1 protein profile. “Loss” of BCL2 and “gain” of MUM1 is observed in EZH2 high group (BCL2 negative: 48.0%, 12/25 vs. 22.0%, 11/50; MUM1 positive: 44.0%, 11/25 vs. 20.0%, 10/50). Expressions of MYC and p53 are strongly significant for the EZH high group (MYC positive: 76.0%, 19/25 vs. 8.0%, 4/50; p53 positive: 56.0%, 14/25 vs. 6.0%, 3/50). Eventually, FLs with high EZH expression exhibited lower BCL2 and higher MUM1, MYC, and p53 levels. The characteristic immunohistochemical profile of FL with EZH2 high expression is depicted in Figure 4. The clinical and histopathological characteristics according stratified EZH2 expression profile are summarized in Table I.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Immunohistochemical profile of follicular lymphoma (FL): (A) Hematoxylin & eosin staining of FL, follicular type, high grade, grade 3a (200×); (B) EZH2 high expression profile (200×); (C) MUM1 high expression profile (200×); (D) MYC higher expression (200×); (E) BCL2 low expression (compare with a strong expression on reactive T-cells in the left bottom corner) (200×); (F) p53 high expression (compare control tissue – negative reactive T-cells in the left bottom corner) (200×).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

The clinical and histopathological characteristics of the stratified EZH2 expression.

POD24 is not related to EZH2 expression profile or FL immunophenotype. The stratification with POD24 shows a similar clinical profile of patients. The EZH high expression profile is nearly the same for patients with and without POD24 (43.8%, 7/16 vs. 36.8%, 14/38). The FL histological grading and patterns do not influence POD24. The FL immunophenotype is not predictive for the identification of POD24 high-risk patients. The characteristics of the stratified POD24 cohorts are depicted in Table II.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

The characteristics of the stratified POD24 cohorts.

Discussion

Regardless of the overall survival improvement in FL still, the leading cause of death is lymphoma and its transformation. In 10-year observation studies, the worst outcome concerns patients with high FLIPI1 score, with transformed disease to DLBCL and those who did not achieve event free-survival within 12 and 24 months of diagnosis (9, 10, 13, 47, 48). The prediction of POD24 and risk of relapse and progression reflects the need for a revised investigation of predictive and prognostic markers.

Our analysis revealed that EZH2 immunohistochemical expression was independent of clinical status. In the POD24 subgroups, age, gender, LDH, hemoglobin levels, Ann Arbor, FLIPI1, and FLIPI2 were not significant. The EZH2 high or low protein levels have no impact on POD24 and TTFT24. However, patients who progressed on treatment within the first 24 months had significantly worse overall survival. Our data confirm that POD24 is the most potent factor for outcome monitoring.

The clinical impact of EZH2 status is thought to be a leading predictive marker for targeted treatment selection (36). The GALLIUM trial within the m7-FLIPI, mutations in EZH2 revealed the highest impact and were associated with longer PFS (HR 0.25, p=0.0036) in CHOP/CVP-treated patients, but not in Bendamustine-treated patients (HR 1.11, p=0.71) (36). Morschhauser et al. were the first who showed results of tazemetostat for high-risk patients whose disease progresses within 24 months of diagnosis (48). The open-label, multicenter, phase 2 study (NCT01897571) included patients with relapsed/refractory FL with or without EZH2 mutation (MT EZH2, n=45, POD24, n=17, 38%; WT EZH2, n=54, POD24, n=30, 56%, respectively). The objective response rate, partial response, progression-free survival, and the median duration of the response for POD24 groups MT vs. WT were: 65% vs. 30%, 59% vs. 30%, 13.8 months vs. 5.6 months, 8.2 months vs. 7.3 months, respectively (48). That has confirmed the influence of EZH2 mutation on treatment results, but the expectations were much greater (39, 49). The latest disappointing result of EZH2-mutant DLBCL treatment with tazemetostat monotherapy has stressed the need to develop other biomarkers and further explore the translational mechanisms related to EZH2 (50). Akpa et al. established the sensitivity of lymphoma cell lines to indirect EZH2 inhibitor - 3-deazaneplanocin A (DZNep); the apoptosis was not EZH2 mutation-dependent at all. Moreover, MYC, BCL2, and BCL6 gene status did not influence the efficacy of DZNep in lymphoma cell line selective apoptosis (51). Recently, Huang et al. showed that in solid tumors, EZH2 intervention could influence numerous epigenetic histone modifications. In preclinical models, the role of oncogenic transcriptional reprogramming mediated by MLL1 interaction with the p300/CBP complex has been described; it is responsible for H3K27me loss and H3K27ac gain, which restricts the response for EZH2 inhibitors (52). Moreover, blockade of both H3K27me and H3K27ac is related to MAPK pathway repression. The authors presented a model based on EZH2 overexpression stratified into three treatment groups: EZH2-monotherapy or with BRD4 inhibitors/p300 inhibitors (double-combo) or a triple combination plus MAPK pathway inhibitors (triple-combo). The combination of agents targeting the epigenome seems to be more efficient. Initial results on DLBCL cell lines with BCL2 and EZH2 inhibition with venetoclax and tazemetostat showed a synergistic antitumor effect as well (53). In the future, personalized anti-EZH2 therapy in relapsed/refractory FL will probably mostly emphasize incorporating different agents to increase response duration.

The biology of EZH2 in the non-hematological and lymphoid malignancies is not fully understood. In solid tumors. i.e., urothelial, prostate, breast, ovarian, endometrial colorectal cancers and melanoma, the aberrant EZH2 protein overexpression assessed immunohistochemically was associated with aggressive clinical behavior and inferior follow-up including shorter time to recurrence or death as endpoints (15, 22, 23, 25, 27, 30, 54-58). Interestingly, EZH2 showed polarization of expression in some tumors, i.e., colorectal cancer tumor invasion front showed EZH2 loss and correlated with poor clinical outcome (55). The latest promising results in myelodysplastic syndromes displayed that both EZH2 mutation and protein loss was related to poor survival, independently of the Revised International Prognostic Scoring System. The authors indicated that EZH2 protein expression demonstrated even more statistical significance with survival than mutational status (59).

In FL, the EZH2 complex regulates normal hematopoietic stem-cell and B-cell renewal and differentiation. There are only a few publications in which EZH2 expression profile has been presented (29, 60). Some studies are convincing that high EZH2 protein levels, i.e., in Burkitt lymphoma, DLBCL, high-grade FL, correlate with increased proliferation, aggressiveness, and poor prognosis (29, 39, 41, 43). Those observations are practically ignoring the role of EZH2 in germinal center B cell development. During lymphopoiesis, EZH2 protein is strongly expressed in proliferating germinal center B cells; it can be observed on control tissues like reactive germinal centers in lymph nodes or tonsils (61). The FL is GC-derived lymphoma, and restoration of EZH2 on protein level is a reminiscence of the cell of origin. There is strong evidence that EZH2 cooperates with BCL2 in the generation of GC-derived lymphomas (62). The loss of EZH2 might signal the more in-depth biological remodeling of the FL; the down-regulation during B-cell differentiation and maturation might be based on changing the mechanism which controls the pro-B to pre-B cell transition (33). Still, the role of EZH2 gain or loss function mutations are observed, but that is only one mechanism of redirecting its tumor-suppressive role in malignancy development. Recent studies show EZH2 in light of post-transcriptional, post-translational, and immunomodulating levels (63).

We showed that EZH2 protein loss in vivo is independent of histopathological features. EZH2 expression seems to be decreased in follicular and diffuse FL patterns as well as low and high-grade subtypes. We showed that EZH2 restoration is more visible on cells with centroblasts morphology. B cells transiting the GC reaction manifest phenotypic features that mimic many of the canonical biological hallmarks of lymphoma. Van Galen at al. showed in the hyperplastic, nonmalignant tonsils that the EZH2 was expressed in the dividing follicular cells with the staining profile of centroblasts (64). The EZH2-mediating epigenetic silencing promotes GC B cell proliferation and prevents differentiation, which are two essential features of the so-called “dark zone” program. The “dark zone” is a histologically and functionally compartment of the GC in which B cells proliferate extensively and undergo immunoglobulin somatic hypermutation (65, 66). The EZH2 protein profile is not fully characterized among patients with FL. On the one hand, immunohistochemically, it is supposed to be overexpressed according to the well-known EZH2 role in GC B cell lymphoma formation; on the contrary, it is “reserved” for more aggressive B-cell lymphomas; however, in low-grade FL the centroblasts are highly EZH2 positive cells (29).

We observed the differences in FL cell immunohistochemical characteristics, including BCL2, MUM1, MYC, and p53. The FL with high EZH2 expression showed “loss” of BCL2 and “gain” of MUM1, MYC, and p53. The mechanisms of EZH2 expression models in vitro studies and mice showed close cooperation with BCL2 and BCL6 (31, 67). The earliest known oncogenic event is the t(14;18)(q32;q21), which covers the BCL2 gene and results in BCL2 protein expression. FL cases with aberrant loss of BCL2 translocation and protein expression are presenting as activated B cell-like (ABC) lymphoma with NFκB activation (68). The absence of BCL2 at the time of diagnosis is associated with transformation to ABC-like large B cell lymphoma, which occurs in a minority of FL progressing cases (69). In FL, MUM1 positivity could be a hallmark of early transformation to DLBCL. Moreover, MUM1 higher expression was an independent predictive factor for progression (69) and was associated with poor OS and PFS (70). In DLBCL groups, EZH2 positivity was related to MUM1 expression, which favored a non-germinal center-like phenotype (41). MYC is responsible for EZH2 up-regulation through EZH2-targeting miRNAs, i.e., miR-26a, miR-26b, or miR-101 (71, 72). On the contrary, EZH2 induces MYC expression by miR-494 and serine biosynthesis pathway (42); those interactions seem to be fundamental in the maintenance of metabolic and epigenetic reprogramming of lymphoma cells. Additionally, the cell-cycle progression of GC B cells is down-regulated by tumor suppressors such as TP53. Lately, Kridel et al. described that FL patients harboring relatively uncommon gene mutations associated with early progression, including TP53 (69). Previously, the presence of TP53 mutation at diagnosis of FL was identified as a high-risk group of patients with shortened time to disease progression and more reduced OS. However, the TP53 was described only in approximately 6% of all cases (73, 74). Zhao et al. has classified the EZH2 as a p53 mRNA-binding protein (75). In vitro studies showed that EZH2 could “boost” p53 gain-of-function mutant-mediated cancer growth and metastasis (75, 76). In cultured human cancer cells, mouse tumor xenografts, and cancer patient specimens (brain tumor, colorectal and pancreatic cancer, sarcoma), EZH2 increased p53 protein levels, enhancing mRNA stability and protein translation (75, 77).

Conclusion

We present, for the first time, the EZH2 expression profile in FL according to POD24 and TTFT24 grouping. We did not observe any statistically significant influence of EZH2 on clinical outcomes. None of the clinical or histopathological features had a high significance onto POD24 and TTFT24. However, POD24 stratification of patients allowed us to confirm its crucial clinical impact in the retrieval of patients who should stay under intensive observation. EZH2 protein is mainly restored within centroblasts-like cells, but EZH2 loss was seen independently of histopathological grade and pattern. We found that EZH2 high levels are more frequently identified in cases with lower BCL2 and higher MUM1, MYC, p53 protein expression. We are pointing out that not only genetic and epigenetic abnormalities of EZH2 should be evaluated since recent studies have shown that targeted therapy seems to remain beneficial regardless of EZH2 status. The role of EZH2 in lymphoid oncogenesis, mediation, and tumor transformation is still one of the fundamental fields for further investigation.

Acknowledgments

Preliminary results of this study were presented as a poster (no 74— LYS-P), European Hematopathology Congress EAHP 2018, 29 September – 4 October 2018, Edinburgh, Scotland, United Kingdom; an oral presentation (no 004) in Oral Free Paper Session - Joint Session: Molecular pathology/Haematopathology at the 31st European Congress of Pathology, 7–11 September 2019, Nice, France. The Project infrastructure POIG.02.03.00-14-111/13 funded by Operational Programme Innovative Economy 2007-2013, Priority II. R&D Infrastructure, Measure 2.3. Investments connected with development of IT infrastructure of Science was implemented.

Footnotes

  • Authors’ Contributions

    Study concepts and study design, data analysis and interpretation, quality control of data and algorithms: A.S.-C., E.P.-K., J.P; data acquisition: A.S.-C., J.P., E.P.-K., G.R., K.S., M.Ko., D.O., M.Ka., B.P.; investigation: A.S.-C., J.P., E.P.-K., K.S., D.O., M.Ka., B.P., M.P.-S.; statistical analysis, visualization of the results: A.S.-C., J.P; manuscript preparation: A.S.-C., manuscript editing and review: A.S.-C., J.P., E.P.-K., G.R., K.S., M.Ko., D.O., M.Ka. B.P., J.W., M.P.-S. All Authors approved the manuscript.

  • Conflicts of Interest

    The Authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

  • Funding

    This work was supported by Maria-Sklodowska Curie National Research Institute of Oncology statutory funding.

  • Received September 30, 2020.
  • Revision received October 13, 2020.
  • Accepted October 15, 2020.
  • Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Salles G,
    2. Seymour JF,
    3. Offner F,
    4. Lopez-Guillermo A,
    5. Belada D,
    6. Xerri L,
    7. Feugier P,
    8. Bouabdallah R,
    9. Catalano JV,
    10. Brice P,
    11. Caballero D,
    12. Haioun C,
    13. Pedersen LM,
    14. Delmer A,
    15. Simpson D,
    16. Leppa S,
    17. Soubeyran P,
    18. Hagenbeek A,
    19. Casasnovas O,
    20. Intragumtornchai T,
    21. Ferme C,
    22. da Silva MG,
    23. Sebban C,
    24. Lister A,
    25. Estell JA,
    26. Milone G,
    27. Sonet A,
    28. Mendila M,
    29. Coiffier B and
    30. Tilly H
    : Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (prima): A phase 3, randomised controlled trial. Lancet 377(9759): 42-51, 2011. PMID: 21176949. DOI: 10.1016/s0140-6736(10)62175-7
    OpenUrlCrossRefPubMed
    1. Press OW,
    2. Unger JM,
    3. Rimsza LM,
    4. Friedberg JW,
    5. LeBlanc M,
    6. Czuczman MS,
    7. Kaminski M,
    8. Braziel RM,
    9. Spier C,
    10. Gopal AK,
    11. Maloney DG,
    12. Cheson BD,
    13. Dakhil SR,
    14. Miller TP and
    15. Fisher RI
    : Phase iii randomized intergroup trial of chop plus rituximab compared with chop chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: Swog s0016. J Clin Oncol 31(3): 314-320, 2013. PMID: 23233710. DOI: 10.1200/jco.2012.42.4101
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Casulo C,
    2. Byrtek M,
    3. Dawson KL,
    4. Zhou X,
    5. Farber CM,
    6. Flowers CR,
    7. Hainsworth JD,
    8. Maurer MJ,
    9. Cerhan JR,
    10. Link BK,
    11. Zelenetz AD and
    12. Friedberg JW
    : Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the national lymphocare study. J Clin Oncol 33(23): 2516-2522, 2015. PMID: 26124482. DOI: 10.1200/jco.2014.59.7534
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Montoto S,
    2. Lopez-Guillermo A,
    3. Altes A,
    4. Perea G,
    5. Ferrer A,
    6. Camos M,
    7. Villela L,
    8. Bosch F,
    9. Esteve J,
    10. Cervantes F,
    11. Blade J,
    12. Nomdedeu B,
    13. Campo E,
    14. Sierra J and
    15. Montserrat E
    : Predictive value of follicular lymphoma international prognostic index (flipi) in patients with follicular lymphoma at first progression. Ann Oncol 15(10): 1484-1489, 2004. PMID: 15367408. DOI: 10.1093/annonc/mdh406
    OpenUrlCrossRefPubMed
  4. ↵
    1. Solal-Celigny P,
    2. Roy P,
    3. Colombat P,
    4. White J,
    5. Armitage JO,
    6. Arranz-Saez R,
    7. Au WY,
    8. Bellei M,
    9. Brice P,
    10. Caballero D,
    11. Coiffier B,
    12. Conde-Garcia E,
    13. Doyen C,
    14. Federico M,
    15. Fisher RI,
    16. Garcia-Conde JF,
    17. Guglielmi C,
    18. Hagenbeek A,
    19. Haioun C,
    20. LeBlanc M,
    21. Lister AT,
    22. Lopez-Guillermo A,
    23. McLaughlin P,
    24. Milpied N,
    25. Morel P,
    26. Mounier N,
    27. Proctor SJ,
    28. Rohatiner A,
    29. Smith P,
    30. Soubeyran P,
    31. Tilly H,
    32. Vitolo U,
    33. Zinzani PL,
    34. Zucca E and
    35. Montserrat E
    : Follicular lymphoma international prognostic index. Blood 104(5): 1258-1265, 2004. PMID: 15126323. DOI: 10.1182/blood-2003-12-4434
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Swerdlow SH,
    2. Campo E,
    3. Harris NL,
    4. Jaffe ES,
    5. Pileri SA,
    6. Stein H and
    7. Thiele J
    : Who classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). IARC: Lyon, 2017.
  6. ↵
    1. Pastore A,
    2. Jurinovic V,
    3. Kridel R,
    4. Hoster E,
    5. Staiger AM,
    6. Szczepanowski M,
    7. Pott C,
    8. Kopp N,
    9. Murakami M,
    10. Horn H,
    11. Leich E,
    12. Moccia AA,
    13. Mottok A,
    14. Sunkavalli A,
    15. Van Hummelen P,
    16. Ducar M,
    17. Ennishi D,
    18. Shulha HP,
    19. Hother C,
    20. Connors JM,
    21. Sehn LH,
    22. Dreyling M,
    23. Neuberg D,
    24. Moller P,
    25. Feller AC,
    26. Hansmann ML,
    27. Stein H,
    28. Rosenwald A,
    29. Ott G,
    30. Klapper W,
    31. Unterhalt M,
    32. Hiddemann W,
    33. Gascoyne RD,
    34. Weinstock DM and
    35. Weigert O
    : Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16(9): 1111-1122, 2015. PMID: 26256760. DOI: 10.1016/s1470-2045(15)00169-2
    OpenUrlCrossRefPubMed
  7. ↵
    1. Sorigue M,
    2. Oliveira A,
    3. Mercadal S,
    4. Tapia G,
    5. Climent F,
    6. Perez-Roca L,
    7. Lorences I,
    8. Domingo-Domenech E,
    9. Cabezon M,
    10. Navarro JT,
    11. Gonzalez-Barca E,
    12. Zamora L,
    13. Ribera JM,
    14. Sureda A,
    15. Armengol MP and
    16. Sancho JM
    : M7flipi and targeted sequencing in high-risk follicular lymphoma. Hematol Oncol 37(5): 564-568, 2019. PMID: 31475375. DOI: 10.1002/hon.2674
    OpenUrlCrossRef
  8. ↵
    1. Jurinovic V,
    2. Kridel R,
    3. Staiger AM,
    4. Szczepanowski M,
    5. Horn H,
    6. Dreyling MH,
    7. Rosenwald A,
    8. Ott G,
    9. Klapper W,
    10. Zelenetz AD,
    11. Barr PM,
    12. Friedberg JW,
    13. Ansell S,
    14. Sehn LH,
    15. Connors JM,
    16. Gascoyne RD,
    17. Hiddemann W,
    18. Unterhalt M,
    19. Weinstock DM and
    20. Weigert O
    : Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128(8): 1112-1120, 2016. PMID: 27418643. DOI: 10.1182/blood-2016-05-717355
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Casulo C,
    2. Le-Rademacher J,
    3. Dixon J,
    4. Salles G,
    5. Hoster E,
    6. Herold M,
    7. Hiddemann W,
    8. Sebban C,
    9. Marcus R,
    10. Kimby E,
    11. Hochster H,
    12. Vitolo U,
    13. Gyan E,
    14. Ou F-S,
    15. Nielsen T,
    16. Foon KA,
    17. Qiuan S and
    18. Flowers C
    : Validation of pod24 as a robust early clinical endpoint of poor survival in follicular lymphoma: Results from the follicular lymphoma analysis of surrogacy hypothesis (flash) investigation using individual data from 5,453 patients on 13 clinical trials. Blood 130(Suppl 1): 412-412, 2017. DOI: 10.1182/blood.V130.Suppl_1.412.412
    OpenUrlCrossRef
  10. ↵
    1. Lansigan F,
    2. Barak I,
    3. Pitcher B,
    4. Jung S-H,
    5. Cheson BD,
    6. Czuczman M,
    7. Martin P,
    8. Hsi E,
    9. Schöder H,
    10. Smith S,
    11. Bartlett NL,
    12. Leonard JP and
    13. Blum KA
    : The prognostic significance of pfs24 in follicular lymphoma following first-line immunotherapy: A combined analysis of 3 calgb trials. Cancer Med 8(1): 165-173, 2019. DOI: 10.1002/cam4.1918
    OpenUrlCrossRef
  11. ↵
    1. Batlevi CL,
    2. Sha F,
    3. Alperovich A,
    4. Ni A,
    5. Smith K,
    6. Ying Z,
    7. Gerecitano JF,
    8. Hamlin PA,
    9. Horwitz SM,
    10. Joffe E,
    11. Kumar A,
    12. Matasar MJ,
    13. Moskowitz AJ,
    14. Moskowitz CH,
    15. Noy A,
    16. Owens C,
    17. Palomba LM,
    18. Straus D,
    19. von Keudell G,
    20. Zelenetz AD,
    21. Seshan VE,
    22. Luminari S,
    23. Marcheselli L,
    24. Federico M and
    25. Younes A
    : Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer 126: 78-90, 2020. PMID: 31927165. DOI: 10.1016/j.ejca.2019.12.006
    OpenUrlCrossRef
  12. ↵
    1. Tobin JWD,
    2. Keane C,
    3. Gunawardana J,
    4. Mollee P,
    5. Birch S,
    6. Hoang T,
    7. Lee J,
    8. Li L,
    9. Huang L,
    10. Murigneux V,
    11. Fink JL,
    12. Matigian N,
    13. Vari F,
    14. Francis S,
    15. Kridel R,
    16. Weigert O,
    17. Haebe S,
    18. Jurinovic V,
    19. Klapper W,
    20. Steidl C,
    21. Sehn LH,
    22. Law SC,
    23. Wykes MN and
    24. Gandhi MK
    : Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. J Clin Oncol 37(34): 3300-3309, 2019. PMID: 31461379. DOI: 10.1200/jco.18.02365
    OpenUrlCrossRef
  13. ↵
    1. Reijm EA,
    2. Timmermans AM,
    3. Look MP,
    4. Meijer-van Gelder ME,
    5. Stobbe CK,
    6. van Deurzen CH,
    7. Martens JW,
    8. Sleijfer S,
    9. Foekens JA,
    10. Berns PM and
    11. Jansen MP
    : High protein expression of ezh2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol 25(11): 2185-2190, 2014. PMID: 25193989. DOI: 10.1093/annonc/mdu391
    OpenUrlCrossRefPubMed
  14. ↵
    1. Inari H,
    2. Suganuma N,
    3. Kawachi K,
    4. Yoshida T,
    5. Yamanaka T,
    6. Nakamura Y,
    7. Yoshihara M,
    8. Nakayama H,
    9. Yamanaka A,
    10. Masudo K,
    11. Oshima T,
    12. Yokose T,
    13. Rino Y,
    14. Shimizu S,
    15. Miyagi Y and
    16. Masuda M
    : Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions. BMC Cancer 17(1): 160, 2017. PMID: 28241804. DOI: 10.1186/s12885-017-3154-3
    OpenUrlCrossRef
    1. Guo S,
    2. Li X,
    3. Rohr J,
    4. Wang Y,
    5. Ma S,
    6. Chen P and
    7. Wang Z
    : Ezh2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features. Diagn Pathol 11: 41, 2016. PMID: 27113214. DOI: 10.1186/s13000-016-0491-5
    OpenUrlCrossRef
    1. Nie L,
    2. Wei Y,
    3. Zhang F,
    4. Hsu YH,
    5. Chan LC,
    6. Xia W,
    7. Ke B,
    8. Zhu C,
    9. Deng R,
    10. Tang J,
    11. Yao J,
    12. Chu YY,
    13. Zhao X,
    14. Han Y,
    15. Hou J,
    16. Huo L,
    17. Ko HW,
    18. Lin WC,
    19. Yamaguchi H,
    20. Hsu JM,
    21. Yang Y,
    22. Pan DN,
    23. Hsu JL,
    24. Kleer CG,
    25. Davidson NE,
    26. Hortobagyi GN and
    27. Hung MC
    : Cdk2-mediated site-specific phosphorylation of ezh2 drives and maintains triple-negative breast cancer. Nat Commun 10(1): 5114, 2019. PMID: 31704972. DOI: 10.1038/s41467-019-13105-5
    OpenUrlCrossRef
  15. ↵
    1. Nakayama H,
    2. Kawachi K,
    3. Suganuma N,
    4. Yoshida T,
    5. Yamashita T,
    6. Yamanaka T,
    7. Matsubara Y,
    8. Kohagura K,
    9. Toda S,
    10. Nakamura Y,
    11. Miyagi Y,
    12. Rino Y and
    13. Masuda M
    : Ezh2 and mmset were identified as potentially useful therapeutic targets in metaplastic breast carcinoma. Anticancer Res 40(4): 2133-2139, 2020. PMID: 32234906. DOI: 10.21873/anticanres.14172
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Yonemitsu Y,
    2. Imazeki F,
    3. Chiba T,
    4. Fukai K,
    5. Nagai Y,
    6. Miyagi S,
    7. Arai M,
    8. Aoki R,
    9. Miyazaki M,
    10. Nakatani Y,
    11. Iwama A and
    12. Yokosuka O
    : Distinct expression of polycomb group proteins ezh2 and bmi1 in hepatocellular carcinoma. Hum Pathol 40(9): 1304-1311, 2009. PMID: 19386347. DOI: 10.1016/j.humpath.2009.01.017
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hajosi-Kalcakosz S,
    2. Dezso K,
    3. Bugyik E,
    4. Bodor C,
    5. Paku S,
    6. Pavai Z,
    7. Halasz J,
    8. Schlachter K,
    9. Schaff Z and
    10. Nagy P
    : Enhancer of zeste homologue 2 (ezh2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagn Pathol 7: 86, 2012. PMID: 22809481. DOI: 10.1186/1746-1596-7-86
    OpenUrlCrossRefPubMed
  18. ↵
    1. Xu J,
    2. Wang Z,
    3. Lu W,
    4. Jiang H,
    5. Lu J,
    6. Qiu J and
    7. Ye G
    : Ezh2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract 215(6): 152374, 2019. PMID: 30952377. DOI: 10.1016/j.prp.2019.03.003
    OpenUrlCrossRef
  19. ↵
    1. Zhou X,
    2. Liu N,
    3. Zhang J,
    4. Ji H,
    5. Liu Y,
    6. Yang J and
    7. Chen Z
    : Increased expression of ezh2 indicates aggressive potential of urothelial carcinoma of the bladder in a chinese population. Sci Rep 8(1): 17792, 2018. PMID: 30542123. DOI: 10.1038/s41598-018-36164-y
    OpenUrlCrossRef
  20. ↵
    1. Singla N,
    2. Krabbe LM,
    3. Aydin AM,
    4. Panwar V,
    5. Woldu SL,
    6. Freifeld Y,
    7. Wood CG,
    8. Karam JA,
    9. Weizer AZ,
    10. Raman JD,
    11. Remzi M,
    12. Rioux-Leclercq N,
    13. Haitel A,
    14. Roscigno M,
    15. Bolenz C,
    16. Bensalah K,
    17. Sagalowsky AI,
    18. Shariat SF,
    19. Lotan Y,
    20. Bagrodia A,
    21. Kapur P and
    22. Margulis V
    : Multi-institutional evaluation of the prognostic significance of ezh2 expression in high-grade upper tract urothelial carcinoma. Urol Oncol 36(7): 343 e341-343 e348, 2018. PMID: 29748098. DOI: 10.1016/j.urolonc.2018.04.004
    OpenUrlCrossRef
  21. ↵
    1. Gorodetska I,
    2. Lukiyanchuk V,
    3. Peitzsch C,
    4. Kozeretska I and
    5. Dubrovska A
    : Brca1 and ezh2 cooperate in regulation of prostate cancer stem cell phenotype. Int J Cancer 145(11): 2974-2985, 2019. PMID: 30968962. DOI: 10.1002/ijc.32323
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wu X,
    2. Scott H,
    3. Carlsson SV,
    4. Sjoberg DD,
    5. Cerundolo L,
    6. Lilja H,
    7. Prevo R,
    8. Rieunier G,
    9. Macaulay V,
    10. Higgins GS,
    11. Verrill CL,
    12. Lamb AD,
    13. Cunliffe VT,
    14. Bountra C,
    15. Hamdy FC and
    16. Bryant RJ
    : Increased ezh2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate 79(10): 1079-1089, 2019. PMID: 31104332. DOI: 10.1002/pros.23817
    OpenUrlCrossRef
  23. ↵
    1. Cheng Y,
    2. Li Y,
    3. Huang X,
    4. Wei W and
    5. Qu Y
    : Expression of ezh2 in uveal melanomas patients and associations with prognosis. Oncotarget 8(44): 76423-76431, 2017. PMID: 29100322. DOI: 10.18632/oncotarget.19462
    OpenUrlCrossRef
  24. ↵
    1. Hoffmann F,
    2. Niebel D,
    3. Aymans P,
    4. Ferring-Schmitt S,
    5. Dietrich D and
    6. Landsberg J
    : H3k27me3 and ezh2 expression in melanoma: Relevance for melanoma progression and response to immune checkpoint blockade. Clin Epigenetics 12(1): 24, 2020. PMID: 32041674. DOI: 10.1186/s13148-020-0818-7
    OpenUrlCrossRef
  25. ↵
    1. Deng Y,
    2. Chen X,
    3. Huang C,
    4. Chen G,
    5. Chen F,
    6. Lu J,
    7. Shi X,
    8. He C,
    9. Zeng Z,
    10. Qiu Y,
    11. Chen J,
    12. Lin R and
    13. Chen Y
    : Ezh2/bcl-2 coexpression predicts worse survival in diffuse large b-cell lymphomas and demonstrates poor efficacy to rituximab in localized lesions. J Cancer 10(9): 2006-2017, 2019. PMID: 31205561. DOI: 10.7150/jca.29807
    OpenUrlCrossRef
  26. ↵
    1. Tian X,
    2. Pelton A,
    3. Shahsafaei A and
    4. Dorfman DM
    : Differential expression of enhancer of zeste homolog 2 (ezh2) protein in small cell and aggressive b-cell non-hodgkin lymphomas and differential regulation of ezh2 expression by p-erk1/2 and myc in aggressive b-cell lymphomas. Modern Pathology 29(9): 1050-1057, 2016. PMID: 27282353. DOI: 10.1038/modpathol.2016.114
    OpenUrlCrossRef
  27. ↵
    1. Bachmann IM,
    2. Halvorsen OJ,
    3. Collett K,
    4. Stefansson IM,
    5. Straume O,
    6. Haukaas SA,
    7. Salvesen HB,
    8. Otte AP and
    9. Akslen LA
    : Ezh2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2): 268-273, 2006. PMID: 16330673. DOI: 10.1200/jco.2005.01.5180
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Béguelin W,
    2. Popovic R,
    3. Teater M,
    4. Jiang Y,
    5. Bunting KL,
    6. Rosen M,
    7. Shen H,
    8. Yang SN,
    9. Wang L,
    10. Ezponda T,
    11. Martinez-Garcia E,
    12. Zhang H,
    13. Zhang Y,
    14. Verma SK,
    15. McCabe MT,
    16. Ott HM,
    17. Van Aller GS,
    18. Kruger RG,
    19. Liu Y,
    20. McHugh CF,
    21. Scott DW,
    22. Chung YR,
    23. Kelleher N,
    24. Shaknovich R,
    25. Creasy CL,
    26. Gascoyne RD,
    27. Wong KK,
    28. Cerchietti LC,
    29. Levine RL,
    30. Abdel-Wahab O,
    31. Licht JD,
    32. Elemento O and
    33. Melnick AM
    : Ezh2 is required for germinal center formation and somatic ezh2 mutations promote lymphoid transformation. Cancer Cell 23(5): 677-692, 2013. PMID: 23680150. DOI: 10.1016/j.ccr.2013.04.011
    OpenUrlCrossRefPubMed
  29. ↵
    1. van Kemenade FJ,
    2. Raaphorst FM,
    3. Blokzijl T,
    4. Fieret E,
    5. Hamer KM,
    6. Satijn DP,
    7. Otte AP and
    8. Meijer CJ
    : Coexpression of bmi-1 and ezh2 polycomb-group proteins is associated with cycling cells and degree of malignancy in b-cell non-hodgkin lymphoma. Blood 97(12): 3896-3901, 2001. PMID: 11389032. DOI: 10.1182/blood.v97.12.3896
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Su Ih, Basavaraj A,
    2. Krutchinsky AN,
    3. Hobert O,
    4. Ullrich A,
    5. Chait BT and
    6. Tarakhovsky A
    : Ezh2 controls b cell development through histone h3 methylation and igh rearrangement. Nat Immunol 4(2): 124-131, 2003. PMID: 12496962. DOI: 10.1038/ni876
    OpenUrlCrossRefPubMed
  31. ↵
    1. Ryan RJH,
    2. Nitta M,
    3. Borger D,
    4. Zukerberg LR,
    5. Ferry JA,
    6. Harris NL,
    7. Iafrate AJ,
    8. Bernstein BE,
    9. Sohani AR and
    10. Le LP
    : Ezh2 codon 641 mutations are common in bcl2-rearranged germinal center b cell lymphomas. PLoS One 6(12): e28585-e28585, 2011. PMID: 22194861. DOI: 10.1371/journal.pone.0028585
    OpenUrlCrossRef
  32. ↵
    1. Morin RD,
    2. Johnson NA,
    3. Severson TM,
    4. Mungall AJ,
    5. An J,
    6. Goya R,
    7. Paul JE,
    8. Boyle M,
    9. Woolcock BW,
    10. Kuchenbauer F,
    11. Yap D,
    12. Humphries RK,
    13. Griffith OL,
    14. Shah S,
    15. Zhu H,
    16. Kimbara M,
    17. Shashkin P,
    18. Charlot JF,
    19. Tcherpakov M,
    20. Corbett R,
    21. Tam A,
    22. Varhol R,
    23. Smailus D,
    24. Moksa M,
    25. Zhao Y,
    26. Delaney A,
    27. Qian H,
    28. Birol I,
    29. Schein J,
    30. Moore R,
    31. Holt R,
    32. Horsman DE,
    33. Connors JM,
    34. Jones S,
    35. Aparicio S,
    36. Hirst M,
    37. Gascoyne RD and
    38. Marra MA
    : Somatic mutations altering ezh2 (tyr641) in follicular and diffuse large b-cell lymphomas of germinal-center origin. Nat Genet 42(2): 181-185, 2010. PMID: 20081860. DOI: 10.1038/ng.518
    OpenUrlCrossRefPubMed
  33. ↵
    1. Jurinovic V,
    2. Passerini V,
    3. Oestergaard MZ,
    4. Knapp A,
    5. Mundt K,
    6. Araf S,
    7. Richter J,
    8. Fitzgibbon J,
    9. Klapper W,
    10. Marcus RE,
    11. Davies A,
    12. Herold M,
    13. Hiddemann W,
    14. Unterhalt M,
    15. Hoster E and
    16. Weigert O
    : Evaluation of the m7-flipi in patients with follicular lymphoma treated within the gallium trial: Ezh2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Blood 134(Suppl_1): 122-122, 2019. DOI: 10.1182/blood-2019-130208
    OpenUrlCrossRef
  34. ↵
    1. Lockmer S,
    2. Ren W,
    3. Brodtkorb M,
    4. Ostenstad B,
    5. Wahlin BE,
    6. Pan-Hammarstrom Q and
    7. Kimby E
    : M7-flipi is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy. Br J Haematol 188(2): 259-267, 2020. PMID: 31423576. DOI: 10.1111/bjh.16159
    OpenUrlCrossRef
  35. ↵
    1. Béguelin W,
    2. Teater MR,
    3. Meydan C,
    4. Phillip JM and
    5. Melnick A
    : Ezh2 gain-of-function mutations generate a lymphoma-permissive immune niche. Blood 134(Suppl_1): 2768-2768, 2019. DOI: 10.1182/blood-2019-132263
    OpenUrlCrossRef
  36. ↵
    1. Zhou Z,
    2. Gao J,
    3. Popovic R,
    4. Wolniak K,
    5. Parimi V,
    6. Winter JN,
    7. Licht JD and
    8. Chen YH
    : Strong expression of ezh2 and accumulation of trimethylated h3k27 in diffuse large b-cell lymphoma independent of cell of origin and ezh2 codon 641 mutation. Leuk Lymphoma 56(10): 2895-2901, 2015. PMID: 25651430. DOI: 10.3109/10428194.2015.1006220
    OpenUrlCrossRef
  37. ↵
    1. Yu L,
    2. Yu TT and
    3. Young KH
    : Cross-talk between myc and p53 in b-cell lymphomas. Chronic Dis Transl Med 5(3): 139-154, 2019. PMID: 31891126. DOI: 10.1016/j.cdtm.2019.08.001
    OpenUrlCrossRef
  38. ↵
    1. Neves Filho EH,
    2. Hirth CG,
    3. Frederico IA,
    4. Burbano RM,
    5. Carneiro T and
    6. Rabenhorst SH
    : Ezh2 expression is dependent on myc and tp53 regulation in diffuse large b-cell lymphoma. APMIS 128(4): 308-315, 2020. PMID: 31991488. DOI: 10.1111/apm.13029
    OpenUrlCrossRef
  39. ↵
    1. Białopiotrowicz E,
    2. Noyszewska-Kania M,
    3. Kachamakova-Trojanowska N,
    4. Łoboda A,
    5. Cybulska M,
    6. Grochowska A,
    7. Kopczyński M,
    8. Mikula M,
    9. Prochorec-Sobieszek M,
    10. Firczuk M,
    11. Graczyk-Jarzynka A,
    12. Zagożdżon R,
    13. Ząbek A,
    14. Młynarz P,
    15. Dulak J,
    16. Górniak P,
    17. Szydłowski M,
    18. Pyziak K,
    19. Martyka J,
    20. Sroka-Porada A,
    21. Jabłońska E,
    22. Polak A,
    23. Kowalczyk P,
    24. Szumera-Ciećkiewicz A,
    25. Chapuy B,
    26. Rzymski T,
    27. Brzózka K and
    28. Juszczyński P
    : Serine biosynthesis pathway supports myc-mir-494-ezh2 feed-forward circuit necessary to maintain metabolic and epigenetic reprogramming of burkitt lymphoma cells. Cancers (Basel) 12(3), 2020. PMID: 32138178. DOI: 10.3390/cancers12030580
    OpenUrlCrossRef
  40. ↵
    1. Tian X,
    2. Xu J and
    3. Dorfman DM
    : Utility of combined ezh2, p-erk1/2, p-stat, and myc expression in the differential diagnosis of ezh2-positive hodgkin lymphomas and related large b-cell lymphomas. Am J Surg Pathol 43(1): 102-109, 2019. PMID: 30371509. DOI: 10.1097/pas.0000000000001180
    OpenUrlCrossRef
  41. ↵
    1. Dreyling M,
    2. Ghielmini M,
    3. Rule S,
    4. Salles G,
    5. Vitolo U and
    6. Ladetto M
    : Newly diagnosed and relapsed follicular lymphoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 27: v83-v90, 2016. DOI: 10.1093/annonc/mdw400
    OpenUrlCrossRefPubMed
  42. ↵
    1. Walewski J,
    2. Paszkiewicz-Kozik E,
    3. Michalski W,
    4. Rymkiewicz G,
    5. Szpila T,
    6. Butrym A,
    7. Giza A,
    8. Zaucha JM,
    9. Kalinka-Warzocha E,
    10. Wieczorkiewicz A,
    11. Zimowska-Curylo D,
    12. Knopinska-Posluszny W,
    13. Tyczynska A,
    14. Romejko-Jarosinska J,
    15. Dabrowska-Iwanicka A,
    16. Gruszecka B,
    17. Jamrozek-Jedlinska M,
    18. Borawska A,
    19. Holda W,
    20. Porowska A,
    21. Romanowicz A,
    22. Hellmann A,
    23. Stella-Holowiecka B,
    24. Deptala A and
    25. Jurczak W
    : First-liner-cvp versusr-chop induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase iii randomized study by the polish lymphoma research group plrg4. Br J Haematol 188(6): 898-906, 2020. PMID: 31792945. DOI: 10.1111/bjh.16264
    OpenUrlCrossRef
  43. ↵
    1. Dubois S,
    2. Mareschal S,
    3. Picquenot JM,
    4. Viailly PJ,
    5. Bohers E,
    6. Cornic M,
    7. Bertrand P,
    8. Veresezan EL,
    9. Ruminy P,
    10. Maingonnat C,
    11. Marchand V,
    12. Lanic H,
    13. Penther D,
    14. Bastard C,
    15. Tilly H and
    16. Jardin F
    : Immunohistochemical and genomic profiles of diffuse large b-cell lymphomas: Implications for targeted ezh2 inhibitor therapy? Oncotarget 6(18): 16712-16724, 2015. PMID: 25762637. DOI: 10.18632/oncotarget.3154
    OpenUrlCrossRefPubMed
  44. ↵
    1. Freeman CL,
    2. Kridel R,
    3. Moccia AA,
    4. Savage KJ,
    5. Villa DR,
    6. Scott DW,
    7. Gerrie AS,
    8. Ferguson D,
    9. Cafferty F,
    10. Slack GW,
    11. Farinha P,
    12. Skinnider B,
    13. Connors JM and
    14. Sehn LH
    : Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134(9): 761-764, 2019. PMID: 31300404. DOI: 10.1182/blood.2019000258
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Morschhauser F,
    2. Tilly H,
    3. Chaidos A,
    4. Phillips TJ,
    5. Ribrag V,
    6. Campbell P,
    7. Gandhi Laurent D,
    8. Jurczak W,
    9. McKay P,
    10. Opat S,
    11. Radford J,
    12. Whalen J,
    13. Rajarethinam A,
    14. Navia SB,
    15. Adib D and
    16. Salles G
    : Phase 2 multicenter study of tazemetostat, an ezh2 inhibitor, in patients with relapsed or refractory follicular lymphoma. Blood 134(Suppl_1): 123-123, 2019. DOI: 10.1182/blood-2019-128096
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Yamagishi M,
    2. Hori M,
    3. Fujikawa D,
    4. Ohsugi T,
    5. Honma D,
    6. Adachi N,
    7. Katano H,
    8. Hishima T,
    9. Kobayashi S,
    10. Nakano K,
    11. Nakashima M,
    12. Iwanaga M,
    13. Utsunomiya A,
    14. Tanaka Y,
    15. Okada S,
    16. Tsukasaki K,
    17. Tobinai K,
    18. Araki K,
    19. Watanabe T and
    20. Uchimaru K
    : Targeting excessive ezh1 and ezh2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep 29(8): 2321-2337 e2327, 2019. PMID: 31747604. DOI: 10.1016/j.celrep.2019.10.083
    OpenUrlCrossRef
  47. ↵
    1. Italiano A,
    2. Soria JC,
    3. Toulmonde M,
    4. Michot JM,
    5. Lucchesi C,
    6. Varga A,
    7. Coindre JM,
    8. Blakemore SJ,
    9. Clawson A,
    10. Suttle B,
    11. McDonald AA,
    12. Woodruff M,
    13. Ribich S,
    14. Hedrick E,
    15. Keilhack H,
    16. Thomson B,
    17. Owa T,
    18. Copeland RA,
    19. Ho PTC and
    20. Ribrag V
    : Tazemetostat, an ezh2 inhibitor, in relapsed or refractory b-cell non-hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study. Lancet Oncol 19(5): 649-659, 2018. PMID: 29650362. DOI: 10.1016/s1470-2045(18)30145-1
    OpenUrlCrossRef
  48. ↵
    1. Akpa CA,
    2. Kleo K,
    3. Lenze D,
    4. Oker E,
    5. Dimitrova L and
    6. Hummel M
    : Dznep-mediated apoptosis in b-cell lymphoma is independent of the lymphoma type, ezh2 mutation status and myc, bcl2 or bcl6 translocations. PLoS One 14(8), 2019. PMID: 31419226. DOI: 10.1371/journal.pone.0220681
    OpenUrlCrossRef
  49. ↵
    1. Huang X,
    2. Yan J,
    3. Zhang M,
    4. Wang Y,
    5. Chen Y,
    6. Fu X,
    7. Wei R,
    8. Zheng XL,
    9. Liu Z,
    10. Zhang X,
    11. Yang H,
    12. Hao B,
    13. Shen YY,
    14. Su Y,
    15. Cong X,
    16. Huang M,
    17. Tan M,
    18. Ding J and
    19. Geng M
    : Targeting epigenetic crosstalk as a therapeutic strategy for ezh2-aberrant solid tumors. Cell 175(1): 186-199 e119, 2018. PMID: 30220457. DOI: 10.1016/j.cell.2018.08.058
    OpenUrlCrossRef
  50. ↵
    1. Gibbs D,
    2. Van Besien H,
    3. Regan S,
    4. Singh A,
    5. Teater M,
    6. Cesarman E,
    7. Melnick A and
    8. Roth LG
    : Combined ezh2 and bcl2 inhibitors as precision therapy for genetically defined dlbcl subtypes. Blood 134(Suppl_1): 304-304, 2019. DOI: 10.1182/blood-2019-126790
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Harms KL,
    2. Chubb H,
    3. Zhao L,
    4. Fullen DR,
    5. Bichakjian CK,
    6. Johnson TM,
    7. Carskadon S,
    8. Palanisamy N and
    9. Harms PW
    : Increased expression of ezh2 in merkel cell carcinoma is associated with disease progression and poorer prognosis. Hum Pathol 67: 78-84, 2017. PMID: 28739498. DOI: 10.1016/j.humpath.2017.07.009
    OpenUrlCrossRef
  52. ↵
    1. Bohm J,
    2. Muenzner JK,
    3. Caliskan A,
    4. Ndreshkjana B,
    5. Erlenbach-Wunsch K,
    6. Merkel S,
    7. Croner R,
    8. Rau TT,
    9. Geppert CI,
    10. Hartmann A,
    11. Roehe AV and
    12. Schneider-Stock R
    : Loss of enhancer of zeste homologue 2 (ezh2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells. J Cancer Res Clin Oncol 145(9): 2227-2240, 2019. PMID: 31317325. DOI: 10.1007/s00432-019-02977-1
    OpenUrlCrossRef
    1. Nienstedt JC,
    2. Schroeder C,
    3. Clauditz T,
    4. Simon R,
    5. Sauter G,
    6. Muenscher A,
    7. Blessmann M,
    8. Hanken H and
    9. Pflug C
    : Ezh2 overexpression in head and neck cancer is related to lymph node metastasis. J Oral Pathol Med 47(3): 240-245, 2018. PMID: 29285811. DOI: 10.1111/jop.12673
    OpenUrlCrossRef
    1. Masudo K,
    2. Suganuma N,
    3. Nakayama H,
    4. Oshima T,
    5. Rino Y,
    6. Iwasaki H,
    7. Matsuzu K,
    8. Sugino K,
    9. Ito K,
    10. Kondo T,
    11. Nakamura Y,
    12. Yoshihara M,
    13. Masuda M and
    14. Miyagi Y
    : Ezh2 overexpression as a useful prognostic marker for aggressive behaviour in thyroid cancer. In Vivo 32(1): 25-31, 2018. PMID: 29275295. DOI: 10.21873/invivo.11200
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Lobo J,
    2. Rodrigues A,
    3. Antunes L,
    4. Graca I,
    5. Ramalho-Carvalho J,
    6. Vieira FQ,
    7. Martins AT,
    8. Oliveira J,
    9. Jeronimo C and
    10. Henrique R
    : High immunoexpression of ki67, ezh2, and smyd3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer. Urol Oncol 36(4): 161 e167-161 e117, 2018. PMID: 29174711. DOI: 10.1016/j.urolonc.2017.10.028
    OpenUrlCrossRef
  54. ↵
    1. Sakhdari A,
    2. Class C,
    3. Montalban-Bravo G,
    4. Sasaki K,
    5. Bueso-Ramos CE,
    6. Patel KP,
    7. Khoury JD,
    8. Kantarjian HM,
    9. Garcia-Manero G,
    10. Medeiros LJ and
    11. Kanagal-Shamanna R
    : Loss of ezh2 protein expression in myelodysplastic syndrome correlates with ezh2 mutation and portends a worse outcome. Blood 134(Suppl_1): 3016-3016, 2019. DOI: 10.1182/blood-2019-131774
    OpenUrlCrossRef
  55. ↵
    1. Huet S,
    2. Xerri L,
    3. Tesson B,
    4. Mareschal S,
    5. Taix S,
    6. Mescam-Mancini L,
    7. Sohier E,
    8. Carrère M,
    9. Lazarovici J,
    10. Casasnovas O,
    11. Tonon L,
    12. Boyault S,
    13. Hayette S,
    14. Haioun C,
    15. Fabiani B,
    16. Viari A,
    17. Jardin F and
    18. Salles G
    : Ezh2 alterations in follicular lymphoma: Biological and clinical correlations. Blood Cancer J 7(4): e555-e555, 2017. PMID: 28430172. DOI: 10.1038/bcj.2017.32
    OpenUrlCrossRef
  56. ↵
    1. Caganova M,
    2. Carrisi C,
    3. Varano G,
    4. Mainoldi F,
    5. Zanardi F,
    6. Germain P-L,
    7. George L,
    8. Alberghini F,
    9. Ferrarini L,
    10. Talukder AK,
    11. Ponzoni M,
    12. Testa G,
    13. Nojima T,
    14. Doglioni C,
    15. Kitamura D,
    16. Toellner K-M,
    17. Su Ih and
    18. Casola S
    : Germinal center dysregulation by histone methyltransferase ezh2 promotes lymphomagenesis. J Clin Invest 123(12): 5009-5022, 2013. PMID: 24200695. DOI: 10.1172/jci70626
    OpenUrlCrossRefPubMed
  57. ↵
    1. Béguelin W,
    2. Popovic R,
    3. Teater M,
    4. Jiang Y,
    5. Bunting KL,
    6. Rosen M,
    7. Shen H,
    8. Yang SN,
    9. Wang L,
    10. Ezponda T,
    11. Martinez-Garcia E,
    12. Zhang H,
    13. Zheng Y,
    14. Verma SK,
    15. McCabe MT,
    16. Ott HM,
    17. Van Aller GS,
    18. Kruger RG,
    19. Liu Y,
    20. McHugh CF,
    21. Scott DW,
    22. Chung YR,
    23. Kelleher N,
    24. Shaknovich R,
    25. Creasy CL,
    26. Gascoyne RD,
    27. Wong K-K,
    28. Cerchietti L,
    29. Levine RL,
    30. Abdel-Wahab O,
    31. Licht JD,
    32. Elemento O and
    33. Melnick AM
    : Ezh2 is required for germinal center formation and somatic ezh2 mutations promote lymphoid transformation. Cancer Cell 23(5): 677-692, 2013. PMID: 23680150. DOI: 10.1016/j.ccr.2013.04.011
    OpenUrlCrossRefPubMed
  58. ↵
    1. Gan L,
    2. Yang Y,
    3. Li Q,
    4. Feng Y,
    5. Liu T and
    6. Guo W
    : Epigenetic regulation of cancer progression by ezh2: From biological insights to therapeutic potential. Biomark Res 6: 10, 2018. PMID: 29556394. DOI: 10.1186/s40364-018-0122-2
    OpenUrlCrossRef
  59. ↵
    1. van Galen JC,
    2. Dukers DF,
    3. Giroth C,
    4. Sewalt RGAB,
    5. Otte AP,
    6. Meijer CJLM and
    7. Raaphorst FM
    : Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. Eur J Immunol 34(7): 1870-1881, 2004. PMID: 15214035. DOI: 10.1002/eji.200424985
    OpenUrlCrossRefPubMed
  60. ↵
    1. Velichutina I,
    2. Shaknovich R,
    3. Geng H,
    4. Johnson NA,
    5. Gascoyne RD,
    6. Melnick AM and
    7. Elemento O
    : Ezh2-mediated epigenetic silencing in germinal center b cells contributes to proliferation and lymphomagenesis. Blood 116(24): 5247-5255, 2010. PMID: 20736451. DOI: 10.1182/blood-2010-04-280149
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Basso K and
    2. Dalla-Favera R
    : Germinal centres and b cell lymphomagenesis. Nature Rev Immunol 15(3): 172-184, 2015. PMID: 25712152. DOI: 10.1038/nri3814
    OpenUrlCrossRefPubMed
  62. ↵
    1. Béguelin W,
    2. Teater M,
    3. Gearhart MD,
    4. Calvo Fernández MT,
    5. Goldstein RL,
    6. Cárdenas MG,
    7. Hatzi K,
    8. Rosen M,
    9. Shen H,
    10. Corcoran CM,
    11. Hamline MY,
    12. Gascoyne RD,
    13. Levine RL,
    14. Abdel-Wahab O,
    15. Licht JD,
    16. Shaknovich R,
    17. Elemento O,
    18. Bardwell VJ and
    19. Melnick AM
    : Ezh2 and bcl6 cooperate to assemble cbx8-bcor complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis. Cancer Cell 30(2): 197-213, 2016. PMID: 27505670. DOI: 10.1016/j.ccell.2016.07.006
    OpenUrlCrossRef
  63. ↵
    1. Klanova M and
    2. Klener P
    : Bcl-2 proteins in pathogenesis and therapy of b-cell non-hodgkin lymphomas. Cancers (Basel) 12(4): 938, 2020. PMID: 32290241. DOI: 10.3390/cancers12040938
    OpenUrlCrossRef
  64. ↵
    1. Kridel R,
    2. Chan FC,
    3. Mottok A,
    4. Boyle M,
    5. Farinha P,
    6. Tan K,
    7. Meissner B,
    8. Bashashati A,
    9. McPherson A,
    10. Roth A,
    11. Shumansky K,
    12. Yap D,
    13. Ben-Neriah S,
    14. Rosner J,
    15. Smith MA,
    16. Nielsen C,
    17. Giné E,
    18. Telenius A,
    19. Ennishi D,
    20. Mungall A,
    21. Moore R,
    22. Morin RD,
    23. Johnson NA,
    24. Sehn LH,
    25. Tousseyn T,
    26. Dogan A,
    27. Connors JM,
    28. Scott DW,
    29. Steidl C,
    30. Marra MA,
    31. Gascoyne RD and
    32. Shah SP
    : Histological transformation and progression in follicular lymphoma: A clonal evolution study. PLoS Med 13(12): e1002197-e1002197, 2016. PMID: 27959929. DOI: 10.1371/journal.pmed.1002197
    OpenUrlCrossRef
  65. ↵
    1. Xerri L,
    2. Bachy E,
    3. Fabiani B,
    4. Canioni D,
    5. Chassagne-Clément C,
    6. Dartigues-Cuilléres P,
    7. Charlotte F,
    8. Brousse N,
    9. Rousselet MC,
    10. Foussard C,
    11. Brice P,
    12. Feugier P,
    13. Morschhauser F,
    14. Sonet A,
    15. Olive D and
    16. Salles G
    : Identification of mum1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis. Hum Pathol 45(10): 2085-2093, 2014. PMID: 25149549. DOI: 10.1016/j.humpath.2014.06.019
    OpenUrlCrossRefPubMed
  66. ↵
    1. Zhang X,
    2. Zhao X,
    3. Fiskus W,
    4. Lin J,
    5. Lwin T,
    6. Rao R,
    7. Zhang Y,
    8. Chan JC,
    9. Fu K,
    10. Marquez VE,
    11. Chen-Kiang S,
    12. Moscinski LC,
    13. Seto E,
    14. Dalton WS,
    15. Wright KL,
    16. Sotomayor E,
    17. Bhalla K and
    18. Tao J
    : Coordinated silencing of myc-mediated mir-29 by hdac3 and ezh2 as a therapeutic target of histone modification in aggressive b-cell lymphomas. Cancer Cell 22(4): 506-523, 2012. PMID: 23079660. DOI: 10.1016/j.ccr.2012.09.003
    OpenUrlCrossRefPubMed
  67. ↵
    1. Zhao X,
    2. Lwin T,
    3. Zhang X,
    4. Huang A,
    5. Wang J,
    6. Marquez VE,
    7. Chen-Kiang S,
    8. Dalton WS,
    9. Sotomayor E and
    10. Tao J
    : Disruption of mycmirna-ezh2 loop to suppress aggressive b-cell lymphoma survival and clonogenicity. Leukemia 27(12): 2341-2350, 2013. PMID: 23538750. DOI: 10.1038/leu.2013.94
    OpenUrlCrossRef
  68. ↵
    1. O’Shea D,
    2. O’Riain C,
    3. Taylor C,
    4. Waters R,
    5. Carlotti E,
    6. Macdougall F,
    7. Gribben J,
    8. Rosenwald A,
    9. Ott G,
    10. Rimsza LM,
    11. Smeland EB,
    12. Johnson N,
    13. Campo E,
    14. Greiner TC,
    15. Chan WC,
    16. Gascoyne RD,
    17. Wright G,
    18. Staudt LM,
    19. Lister TA and
    20. Fitzgibbon J
    : The presence of tp53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 112(8): 3126-3129, 2008. PMID: 18628487. DOI: 10.1182/blood-2008-05-154013
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Xu P,
    2. Liu X,
    3. Ouyang J and
    4. Chen B
    : Tp53 mutation predicts the poor prognosis of non-hodgkin lymphomas: Evidence from a meta-analysis. PLoS One 12(4): e0174809, 2017. PMID: 28369138. DOI: 10.1371/journal.pone.0174809
    OpenUrlCrossRef
  70. ↵
    1. Zhao Y,
    2. Ding L,
    3. Wang D,
    4. Ye Z,
    5. He Y,
    6. Ma L,
    7. Zhu R,
    8. Pan Y,
    9. Wu Q,
    10. Pang K,
    11. Hou X,
    12. Weroha SJ,
    13. Han C,
    14. Coleman R,
    15. Coleman I,
    16. Karnes RJ,
    17. Zhang J,
    18. Nelson PS,
    19. Wang L and
    20. Huang H
    : Ezh2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J 38(5): e99599, 2019. PMID: 30723117. DOI: 10.15252/embj.201899599
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Iannetti A,
    2. Ledoux AC,
    3. Tudhope SJ,
    4. Sellier H,
    5. Zhao B,
    6. Mowla S,
    7. Moore A,
    8. Hummerich H,
    9. Gewurz BE,
    10. Cockell SJ,
    11. Jat PS,
    12. Willmore E and
    13. Perkins ND
    : Regulation of p53 and rb links the alternative nf-κb pathway to ezh2 expression and cell senescence. PLoS Genet 10(9), 2014. PMID: 25255445. DOI: 10.1371/journal.pgen.1004642
    OpenUrlCrossRefPubMed
  72. ↵
    1. Shiogama S,
    2. Yoshiba S,
    3. Soga D,
    4. Motohashi H and
    5. Shintani S
    : Aberrant expression of ezh2 is associated with pathological findings and p53 alteration. Anticancer Res 33(10): 4309-4317, 2013. PMID: 24122997.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (12)
Anticancer Research
Vol. 40, Issue 12
December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment
ANNA SZUMERA-CIEĆKIEWICZ, JAN POLESZCZUK, EWA PASZKIEWICZ-KOZIK, GRZEGORZ RYMKIEWICZ, KAMIL SOKÓŁ, ANITA BORYSIUK, MARTYNA KOTARSKA, DARIA OWCZAREK, MONIKA KAWECKA, BEATA PYTLAK, JAN WALEWSKI, MONIKA PROCHOREC-SOBIESZEK
Anticancer Research Dec 2020, 40 (12) 6685-6697; DOI: 10.21873/anticanres.14692

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment
ANNA SZUMERA-CIEĆKIEWICZ, JAN POLESZCZUK, EWA PASZKIEWICZ-KOZIK, GRZEGORZ RYMKIEWICZ, KAMIL SOKÓŁ, ANITA BORYSIUK, MARTYNA KOTARSKA, DARIA OWCZAREK, MONIKA KAWECKA, BEATA PYTLAK, JAN WALEWSKI, MONIKA PROCHOREC-SOBIESZEK
Anticancer Research Dec 2020, 40 (12) 6685-6697; DOI: 10.21873/anticanres.14692
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 5-Azacytidine (5-aza) Induces p53-associated Cell Death Through Inhibition of DNA Methyltransferase Activity in Hep3B and HT-29 Cells
  • Prognostic Value of WNT1, NOTCH1, PDGFRβ, and CXCR4 in Oral Squamous Cell Carcinoma
  • Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway
Show more Experimental Studies

Similar Articles

Keywords

  • Follicular lymphoma
  • EZH2
  • POD24
  • time to first systemic therapy
  • prognostic factors
  • expression profile
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire